Comparison of Adverse Event (AE) Management Costs of Chimeric Antigen Receptor T-Cell (CAR T) Therapies in 4L+ Relapsed And/Or Refractory Multiple Myeloma (RRMM) (IMS 2026) - Sep 11, 2026 - Abstract #PA-110; Pres time: Sep 25, 2026; "The objective of this study was to model total per-patient AE management costs of anito-cel, cilta-cel, and ide-cel in 4L+ RRMM from a US health system perspective. In this analysis, anito-cel was associated with the lowest per-patient AE management costs compared with other CAR T therapies in 4L+ RRMM, driven by differences in incidence of high-cost AEs. Findings should be interpreted in the context of cost estimation assumptions and unadjusted cross-trial comparisons, which may also reflect evolving clinical and management practices over time. Overall, these findings highlight the importance of considering safety-related costs alongside clinical outcomes when evaluating CAR T therapies in RRMM."
Adverse events • CAR T-Cell Therapy • Acute Myelogenous Leukemia • CNS Disorders • Gastrointestinal Disorder • Hematological Malignancies • Leukemia • Movement Disorders • Multiple Myeloma • Myelodysplastic Syndrome • Parkinson's Disease
|
|
Rahul Banerjee1; Lekha Mikkilineni2; Avik Ray3; Jie Ting4; Ken Hasegawa5; Samuel Hong5; William Ngantung6; Matia Saeedian6; Matthew J. Frigault7
|